Coherus Oncology IncCHRS
Price$1.16Intrinsic value$2.0981% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $2.09median of 2 methodsbased on filings through 30 Jun 2026
Market Price $1.16Price as of 1 Oct 2026
Margin of Safety +80.5%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 35.5%/yr (balance of the path).28.8% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 629.0%Yr 722.5%Yr 816.0%Yr 99.5%Yr 103.0%
35.5% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (5/6y) (limited history)0.0%
Discount rate (cost of equity) 9.3%
Volatility vs market (adjusted beta)0.96

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetCoherus Oncology IncCHRSHealth Care
Valuation
P/E—
P/S4.1×
P/B3.3×
EV / Revenue3.2×
EV / EBITDA-0.6×
Profitability
Gross margin67.2%
Operating margin-429.5%
Net margin-259.4%
FCF margin-365.2%
Returns
ROE-217.2%
ROA-69.1%
ROIC—
Growth
Revenue growth (YoY)93.0%
5-yr fwd EPS growth28.8%
Financial strength
Debt / Equity0.61×
Current ratio1.77×
Altman Z-Score-11.7
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.